Concepedia

Kiyofumi Honda

KH

Statistics

Publications

8

Citations

498

H-Index

8

Active since

1996

Affiliations

Chugai Pharma (United States)(Current)

Kiyofumi Honda is an author at Chugai Pharma (United States) specializing in pharmacology, sodium-glucose cotransport, and diabetes mellitus.

Publications per year

1996–2018

8

Publications

8

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +17

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

Taku Fukuzawa, Zenjiro Sampei, Kenta Haraya et al. · Scientific Reports · 2017 · 107 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples

Masakazu Sugiyama, Akihiro Kikuchi, Hirofumi Misu et al. · PLoS ONE · 2018 · 54 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +16

SGLT5 Reabsorbs Fructose in the Kidney but Its Deficiency Paradoxically Exacerbates Hepatic Steatosis Induced by Fructose

Taku Fukuzawa, Masanori Fukazawa, Otoya Ueda et al. · PLoS ONE · 2013 · 53 citations · Full text

Life Sciences, Biochemistry, Physiology +17

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

Takumi Nagata, Masanori Fukazawa, Kiyofumi Honda et al. · American Journal of Physiology-Endocrinology and Metabolism · 2012 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +15

1–5 of 8